*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
An Overview of Coronavirus Disease (MERS& SARS): COVID- 19

Author: , SHAKIR BASHA S, SUSMITHA K, JAGADEESH P, SUSMEENA TABASSUM K, JUNAID A.H, FAYAZ AHMMED S, ZUBER R, KHIFAYATHULLA S, ASWINI G
Abstract: In the year 2019, December, a novel Coronavirus (CoV) was identified in the area of Wuhan City, Hubei, China. Coronavirus is a broad community of viruses which have been proven to produce disorders ranging from a simple cold to even more serious disorders, namely severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS). Epidemiological genomic studies including association with some other Coronaviruses resulted in the emergence of novel Coronaviruses, remotely matching the bat Coronaviruses. In distinct countries, COVID-19 epidemics are yet in the seeding up the stage. The SARS- CoV- 2 outbreak would pose a significant threat to the potential survival of public health in 2019&2020. A vaccine against the virus is not yet available. Since the deaths have been increasing and to prevent it from spreading certain measures should be followed. The preventive measures generally include washing your hands regularly, use of facemask, avoid unnecessary contact with animals, and avoid close contact with infected people. Currently, the need for effective instance identification, management, and adequate precautionary measures will be potentially helpful in the management of the epidemic. There are a variety of candidate medications are available, which may inhibit SARS- CoV-2 invasion along with its recombination. The results of the current clinical trials in combination with Hydroxychloroquine, azithromycin, and some other new anti-viral agents such as remdesivir could help to assist a few of the infections, although there is still a long way to go to the results of clinical trials and the use of vaccines in the community healthcare plan.
Keyword: Coronavirus, SARS, MERS, Hydroxychloroquine, Remdesivir.
DOI: https://doi.org/10.31838/ijpr/2021.13.01.123
Download: Request For Article
 
Clients

Clients

Clients

Clients

Clients
ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free